MRTX News and Press, Mirati Therapeutics Inc.

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-06 08:19:58 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: All Focus On Execution Bristol-Myers Squibb: Massive Discount Spells Opportunity Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation Bristol Myers, 2seventy bio ...

2024-01-23 08:51:17 ET More on Bristol-Myers Bristol Myers Squibb: Might Be Approaching A Bottom In 2024 Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also CAR-T therap...

2024-01-19 13:24:22 ET More on Mirati Therapeutics Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition Mirati's Krazati gets EU conditional approval for lung cancer Mirati Therapeutics gains as HSR waiting period for sale to Bristol...

2024-01-10 09:30:57 ET More on Mirati Therapeutics Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires Mirati lung cancer therapy endorsed in EU ...

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...

2024-01-08 14:41:28 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Company (BMY) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bristol-My...

2024-01-07 04:13:27 ET Summary Tango Therapeutics stock experienced a significant increase after positive data from Mirati's synthetic lethality technology. Mirati's data showed promising results in a Phase 1/2 clinical trial of their PRMT5 inhibitor, MRTX1719. Despite the pos...

2024-01-03 07:53:17 ET More on Bristol-Myers Squibb Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management Bristol Myers Squibb: Aggressive M&A, A Riskier Strat...

2023-12-31 02:49:47 ET Summary Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allowing it to expand its drug portfolio and product candi...